LBIO (Longevity Biomedical) Total Assets: $0.00 Mil (As of . 20)


What is Longevity Biomedical Total Assets?

Longevity Biomedical LBIO Total Assets is $0.00 Mil as of . 20.

Longevity Biomedical's Total Assets for the quarter that ended in . 20 was $0.00 Mil.

Total Assets is connected with ROA %. Longevity Biomedical's annualized ROA % for the quarter that ended in . 20 was %. Total Assets is also linked to Revenue through Asset Turnover. Longevity Biomedical's Asset Turnover for the quarter that ended in . 20 was .

Longevity Biomedical  (NAS:LBIO) Total Assets Explanation

Total Assets is connected with ROA %.

Longevity Biomedical's annualized ROA % for the quarter that ended in . 20 is

ROA %=Net Income (Q: . 20 )/( (Total Assets (Q: . 20 )+Total Assets (Q: . 20 ))/ count )
=/( (+)/ )
=/
= %

Note: The Net Income data used here is one times the annual (. 20) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Longevity Biomedical's Asset Turnover for the quarter that ended in . 20 is

Asset Turnover
=Revenue (Q: . 20 )/( (Total Assets (Q: . 20 )+Total Assets (Q: . 20 ))/ count )
=/( (+)/ )
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Longevity Biomedical Total Assets Related Terms

Longevity Biomedical Total Assets Historical Data

* Premium members only.

The historical data trend for Longevity Biomedical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical Total Assets Chart

Longevity Biomedical Annual Data
Trend
Total Assets

Longevity Biomedical Semi-Annual Data
Total Assets

Longevity Biomedical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Longevity Biomedical's Total Assets for the fiscal year that ended in . 20 is calculated as

Total Assets=Total Equity (A: . 20 )+Total Liabilities (A: . 20 )
=N/A+N/A
=N/A

Longevity Biomedical's Total Assets for the quarter that ended in . 20 is calculated as

Total Assets=Total Equity (Q: . 20 )+Total Liabilities (Q: . 20 )
=N/A+N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $0.00 Mil mean?
Longevity Biomedical (LBIO) has a Total Assets of $0.00 Mil as of . 20. The total amount of assets as recorded on a company's balance sheet. View historical data on Longevity Biomedical and its competitors.
Is Longevity Biomedical's Total Assets too high?
Longevity Biomedical's current Total Assets is $0.00 Mil.
How does Longevity Biomedical's Total Assets compare to ?
Longevity Biomedical's Total Assets of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Longevity Biomedical and its competitors. Longevity Biomedical's current Total Assets is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Biomedical stock overvalued right now?
Longevity Biomedical (LBIO) has a current Total Assets of $0.00 Mil. The current Total Assets is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Longevity Biomedical (LBIO), the current Total Assets is $0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Biomedical Business Description

Comparable Companies
Address 12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.